Finerenone in diabetic kidney disease: Findings from a single-center retrospective observational study
Diabetic kidney disease (DKD) remains associated with substantial residual kidney and cardiovascular risk despite renin–angiotensin system blockade and sodium–glucose cotransporter 2 (SGLT2) inhibitor therapy. Routinely collected data from 16 adults with documented DKD who initiated finerenone 10 mg once daily at a s...